- |||||||||| ATL 001 / Achilles Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CHIRON: ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC (clinicaltrials.gov) - Nov 1, 2024
P1/2, N=27, Terminated,
N=50 --> 27 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
- |||||||||| ATL 001 / Achilles Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) - Oct 31, 2024
P1/2, N=13, Terminated,
N=50 --> 27 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision N=40 --> 13 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision
- |||||||||| ATL 001 / Achilles Therap
Trial completion date: THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) - Jan 4, 2024
P1/2, N=40, Recruiting,
N=40 --> 13 | Trial completion date: Jul 2027 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2025 --> Sep 2024; Sponsor decision Trial completion date: Dec 2027 --> Jul 2027
- |||||||||| ATL 001 / Achilles Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Long-Term Follow-Up Study of Patients Receiving ATL001 (clinicaltrials.gov) - Nov 21, 2023
P2, N=1, Terminated,
N=90 --> 1 | Trial completion date: Jul 2028 --> Oct 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Oct 2023; The long-term follow-up of patients is being migrated to the original (parent) study protocols (Trial ID: ATX-NS-001 / NCT: NCT04032847;Trial ID: ATX-ME-001 / NCT: NCT03997474). Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor.
- |||||||||| ATL 001 / Achilles Therap
Trial completion date, Trial primary completion date: CHIRON: ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC (clinicaltrials.gov) - Sep 22, 2023
P1/2, N=50, Recruiting,
Consequently, the ATX-LTFU-001 study is being terminated by the Sponsor. Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
- |||||||||| ATL 001 / Achilles Therap
Trial completion date, Trial primary completion date: THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) - Jan 9, 2023
P1/2, N=40, Recruiting,
Trial completion date: Dec 2023 --> Jul 2027 | Trial primary completion date: Jul 2023 --> Jul 2025 Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025
- |||||||||| ATL 001 / Achilles Therap
Trial initiation date: Long-Term Follow-Up Study of Patients Receiving ATL001 (clinicaltrials.gov) - Feb 16, 2022
P2, N=90, Not yet recruiting,
Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Jul 2025 Initiation date: Jul 2021 --> Jun 2022
- |||||||||| ATL 001 / Achilles Therap
[VIRTUAL] Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program () - Mar 11, 2021 - Abstract #AACR2021AACR_606;
An approach that targets multiple clonal neoantigens with specific T cells has the potential to demonstrate high specificity and efficacy whilst mitigating the risk of immune escape.Achilles Therapeutics is developing a personalized ACT product, ATL001, to target clonal neoantigens, which are identified using tumor exome sequencing and the PELEUS™ bioinformatics platform...The amalgamation of diverse streams of data requires the development of robust processes and systems for data collection, processing and storage. Furthermore, the evaluation of multiple exploratory endpoints will require integration and modelling of baseline covariates, time-series immune-monitoring and efficacy data, all of which will be described
- |||||||||| ATL 001 / Achilles Therap
Trial completion date, Trial primary completion date: THETIS: ATL001 in Patients With Metastatic or Recurrent Melanoma (clinicaltrials.gov) - Feb 11, 2021
P1/2, N=40, Recruiting,
Furthermore, the evaluation of multiple exploratory endpoints will require integration and modelling of baseline covariates, time-series immune-monitoring and efficacy data, all of which will be described Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Jul 2023
- |||||||||| AT-001 / Applied Therap, ATL 001 / Achilles Therap
ATL001 (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_113;
|
